Physician profile
Lauren P Bushue
NPI 1598368540
$3,908.99
in general payments reported to CMS, 2019-2025
22 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 97% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $236 · 2022: $975 · 2023: $786 · 2024: $903 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,604 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,604.06 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $665.25 | 2022-2024 | Ova1 |
| Astellas Pharma US INC | $456.80 | 2023-2025 | Veozah |
| Biogen, INC. | $449.79 | 2023-2025 | Zurzuvae |
| Abbvie INC. | $404.54 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $367.72 | 2022-2025 | |
| Organon LLC | $253.93 | 2021-2025 | Nexplanon, Jada System |
| Exeltis, USA INC. | $187.74 | 2021-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $179.20 | 2021-2025 | |
| Millicent US INC | $167.87 | 2022-2025 | Intrarosa, Femlyv, Femring |
| Shield Therapeutics INC | $160.03 | 2023-2025 | Accrufer |
| Therapeuticsmd, INC. | $121.67 | 2021-2022 | |
| Agile Therapeutics, INC. | $117.20 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $67.42 | 2025 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $63.39 | 2021-2025 | Paragard T 380a |
| Exact Sciences Corporation | $52.64 | 2023-2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Pharmaceuticals INC. | $49.38 | 2021-2022 | |
| Daiichi Sankyo INC. | $46.20 | 2022 | |
| Baxter Healthcare | $35.78 | 2025 | Perclot |
| Pfizer INC. | $23.19 | 2023 | |
| Evofem Biosciences, INC. | $14.01 | 2022 | |
| Hologic Sales and Service, LLC | $12.66 | 2021 | |
| Avion Pharmaceuticals | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Bushue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.